Neuphoria Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2026 to a ratio of 1.33, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2026. Neuphoria Therapeutics Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has decreased to 274 days, from -18250 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector Neuphoria Therapeutics Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Neuphoria Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NEUP Receivables Turnover Ratio	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Receivable Change	6708.09 %	6427.9 %	3021.14 %	-98.48 %	-90.58 %
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	1.33	-	52.21	847.53	332.86
NEUP's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	274	-	7	0	1
Seq. Receivable Change	-49.33 %	44.64 %	63034.7 %	-85.29 %	-51.42 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

NEUP Company Profile • Back to NEUP Efficiency Comparisons • Compare NEUP Receivables Turnover Ratio to its Competitors

Financial Statements
Neuphoria Therapeutics Inc 's Accounts Receivable	$ 1 Millions	Visit NEUP's Balance sheet
Neuphoria Therapeutics Inc 's Sales TTM	$ 1 Millions	Visit NEUP's Income Statement
Sources of NEUP's Revenues		Visit NEUP's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NEUP's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NEUP's Growth Rates	NEUP's Roa	NEUP's Inventory Turnover Ratio	NEUP's Dividend Comparisons
NEUP's Profitability Ratios	NEUP's Roi	NEUP's Asset Turnover Ratio	NEUP's Dividend Growth
NEUP's Valuation Ratios	NEUP's Roe	NEUP's Financial Strength Ratios	NEUP's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Teva Pharmaceutical Industries Limited	3.92	$ 14,105.000 Millions	$ 3,601.250 Millions
Verrica Pharmaceuticals Inc	3.92	$ 30.321 Millions	$ 7.743 Millions
Teleflex Incorporated	3.90	$ 1,628.534 Millions	$ 417.093 Millions
Iovance Biotherapeutics inc	3.90	$ 324.969 Millions	$ 83.272 Millions
Vanda Pharmaceuticals Inc	3.89	$ 215.721 Millions	$ 55.423 Millions
Immunitybio inc	3.87	$ 165.792 Millions	$ 42.832 Millions
Insight Molecular Diagnostics Inc	3.85	$ 1.670 Millions	$ 0.434 Millions
Tonix Pharmaceuticals Holding Corp	3.83	$ 29.102 Millions	$ 7.594 Millions
Urogen Pharma Ltd	3.82	$ 188.317 Millions	$ 49.239 Millions
Akebia Therapeutics Inc	3.82	$ 219.060 Millions	$ 57.324 Millions
Eyepoint Inc	3.79	$ 2.788 Millions	$ 0.735 Millions
Alpha Cognition Inc.	3.78	$ 15.261 Millions	$ 4.034 Millions
Biomarin Pharmaceutical Inc	3.72	$ 3,406.614 Millions	$ 915.860 Millions
Biocorrx Inc	3.72	$ 0.787 Millions	$ 0.211 Millions
Cytek Biosciences Inc	3.72	$ 205.086 Millions	$ 55.186 Millions
Align Technology inc	3.70	$ 4,138.567 Millions	$ 1,118.659 Millions
Ani Pharmaceuticals Inc	3.68	$ 978.379 Millions	$ 265.900 Millions
Autolus Therapeutics Plc	3.65	$ 117.390 Millions	$ 32.171 Millions
Vivosim Labs Inc	3.64	$ 0.112 Millions	$ 0.031 Millions
Procept Biorobotics Corporation	3.62	$ 336.764 Millions	$ 93.008 Millions
Evofem Biosciences Inc	3.61	$ 18.045 Millions	$ 4.993 Millions
Adma Biologics Inc	3.58	$ 510.934 Millions	$ 142.549 Millions
Ss Innovations International Inc	3.55	$ 52.199 Millions	$ 14.717 Millions
Sensus Healthcare Inc	3.55	$ 18.294 Millions	$ 5.159 Millions
Dyadic International Inc	3.50	$ 3.802 Millions	$ 1.085 Millions
Abcellera Biologics Inc	3.44	$ 66.174 Millions	$ 19.210 Millions
Ars Pharmaceuticals Inc	3.41	$ 116.927 Millions	$ 34.325 Millions
Hyperfine Inc	3.40	$ 15.425 Millions	$ 4.537 Millions
Lifeward ltd	3.38	$ 21.822 Millions	$ 6.447 Millions
Krystal Biotech Inc	3.37	$ 440.484 Millions	$ 130.686 Millions

Date modified: 2026-09-19T15:06:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.